Patient Preferences Studies

Heather Benz, Ph.D.
External Expertise and Partnerships
Center for Devices and Radiological Health
US Food and Drug Administration

Partners in Progress
November 13, 2017
Patients are at the Heart of What We Do

Center for Devices and Radiological Health Vision: Patients in the U.S. have access to high-quality, safe, and effective medical devices of public health importance first in the world
Patient Preference

- Patient preferences are defined as qualitative or quantitative assessments of the relative desirability or acceptability to patients of specified alternatives or choices among outcomes or other attributes that differ among alternative health interventions.
- Relevant preferences of care-partners (e.g., parents) and health care professionals may also be considered.

What PPI Can Provide and How It Can Be Used

• PPI data can provide valuable information about:
  • Which benefits and risks are most important to affected patients
  • What benefit-risk tradeoffs are acceptable from the patient perspective
  • How do these patients think about these tradeoffs
  • Are there clinically-relevant subgroups of patients that would accept a particular benefit-risk profile and/or choose one treatment option over other alternatives

• Potential Uses of PPI:
  • Inform endpoints or effect size for regulatory studies
  • Inform subgroup considerations
  • Labeling changes / expanded indications

• Other potential uses outside regulatory context, such as shared medical decision-making.
# Recommended Qualities of Patient Preference Studies

<table>
<thead>
<tr>
<th>Study sample</th>
<th>Study design</th>
<th>Study conduct and analysis</th>
</tr>
</thead>
<tbody>
<tr>
<td>Well-informed patients</td>
<td>Questions are meaningful and relevant to patients</td>
<td>Well-documented instrument development process and study conduct, including the initial qualitative work</td>
</tr>
<tr>
<td>Representative sample for generalizable results</td>
<td>Minimize cognitive bias</td>
<td>Logical soundness (e.g., internal consistency)</td>
</tr>
<tr>
<td>Capturing heterogeneity</td>
<td>Effective benefit-risk communication</td>
<td>Robustness of study results (e.g., sensitivity analysis)</td>
</tr>
<tr>
<td></td>
<td>Demonstrated comprehension by patients</td>
<td></td>
</tr>
</tbody>
</table>
Discrete Choice Question Example: Obesity Devices

Risks

↓ Risk

New Device

↓ Benefit

Weight Loss

## Discrete Choice Question

<table>
<thead>
<tr>
<th>Attribute</th>
<th>Device A</th>
<th>Device B</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Type of operation</strong></td>
<td>Endoscopic Surgery</td>
<td></td>
</tr>
<tr>
<td><strong>Recommended diet restriction</strong></td>
<td>Wait 4 hours between meals</td>
<td></td>
</tr>
<tr>
<td><strong>On average, how much weight is lost</strong></td>
<td>30 lbs.</td>
<td>60 lbs.</td>
</tr>
<tr>
<td><strong>On average, how long weight loss lasts</strong></td>
<td>5 years</td>
<td>1 year</td>
</tr>
<tr>
<td><strong>Average reduction in dose of prescription drugs for diabetes at the lower weight</strong></td>
<td>Eliminates the need for prescription drug</td>
<td></td>
</tr>
<tr>
<td><strong>On average, how long side effects last</strong></td>
<td>1 month</td>
<td>1 year</td>
</tr>
<tr>
<td><strong>Chance of a side effect requiring hospitalization</strong></td>
<td>None</td>
<td></td>
</tr>
<tr>
<td><strong>Chance of dying from getting the weight loss device</strong></td>
<td>![10% (10 out of 100)]</td>
<td>![1% (1 out of 100)]</td>
</tr>
<tr>
<td><strong>Which weight loss device do you think is better for people like you?</strong></td>
<td>![Device A]</td>
<td>![Device B]</td>
</tr>
</tbody>
</table>

(Recall that side effects will limit your ability to do daily activities several times a month)
Example Questions
High intensity focused ultrasound (HIFU) for ablation of prostate tissue in men with localized prostate cancer

— Prostate cancer is the most common malignancy and the third leading cause of cancer-related deaths in men in the United States and Europe.

— FDA recently allowed to market two HIFU tools for prostate tissue ablation after rejecting prior PMA indicated to treat prostate cancer, as they did not demonstrate cancer-specific effectiveness.

— *How to make decisions in the absence of relevant clinical effectiveness data, but in light of known potential adverse events and 12 month post-treatment prostate biopsy data*
What amount of adverse event risk are patients willing to tolerate for increased effectiveness for this treatment?
Rationale / Public Health Need

- Patient perspective on available benefit data or tolerance of risks associated with HIFU may inform future premarket device evaluation of ablation tools.
- Delivery of better ablation devices sooner to patients.

**CDRH Strategic Priority of Partnering with Patients:**

“Increase use and transparency of patient input as evidence in our decision making.”
Submission of PPI to FDA

FDA encourages sponsors and other stakeholders to have early interactions with the relevant FDA review division if considering collecting and submitting PPI.

- Request an informational pre-submission meeting to discuss plans for designing or submitting a patient preference study
- Request participation from Martin.Ho@fda.hhs.gov and Anindita.Saha@fda.hhs.gov